HMGB1 and glioblastoma: The release of HMGB1 as a result of viral-derived ganciclovir tumor cell death activates TLR2 on DCs (immunogenic cell death), resulting in an efficient processing and cross-presentation of tumor antigens leading to tumor regression in a glioblastoma mouse model (98).